Award,contract
Find a Tender
Complete
Save tender
NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
Buyer: NHS England
Deadline
Not available — this notice may describe a possible future opportunity.
Region
Not specified
Value
£166,347,397
Type
Award,contract
SME fit
—
Duration
—
Description
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Awarded to
ACCORD-UK LTD
£166,347,397
AMGEN LIMITED
£166,347,397
AVENTIS PHARMA LIMITED t-a Sanofi
£166,347,397
Bayer PLC
£166,347,397
BIOGEN IDEC LIMITED
£35,312,548
CHUGAI PHARMA LIMITED
£166,347,397
CST PHARMA LIMITED
£166,347,397
ELI LILLY & COMPANY LTD
£166,347,397
GEDEON RICHTER (UK) LIMITED
£166,347,397
GLAXOSMITHKLINE UK LIMITED
£166,347,397
LABORATORIES JUVISE PHARMACEUTICALS
£166,347,397
MERCK SERONO LIMITED
£166,347,397
MILPHARM LIMITED
£166,347,397
NAPP PHARMACEUTICALS LTD
£166,347,397
NOVO NORDISK
£166,347,397
ORIFARM UK LTD
£166,347,397
PFIZER LIMITED
£166,347,397
PHARMACOSMOS UK LTD
£166,347,397
ROCHE PRODUCTS LIMITED
£166,347,397
SANDOZ LIMITED
£35,312,548
Teva UK Limited
£166,347,397
THORNTON & ROSS LIMITED
£166,347,397
Viatris UK Healthcare Ltd
£166,347,397
VIFOR PHARMA UK LTD
£166,347,397
CIPLA (EU) LIMITED
£166,347,397
Quick actions
Key details
- CPV category
- —
- Procurement method
- Open procedure
- Published
- 23 Jun 2026 12:33
- VCSE suitable
- —
Reference
- OCID
- ocds-h6vhtk-051c98
- Notice ID
- C414060
- In our database since
- 17 Aug 2026